期刊文献+

肝癌白细胞抗原-G的表达及其在肝癌肝移植预后中的价值 被引量:1

Expression of Human Leukocyte Antigen-G and Its Prognosis Value for Liver Transplant Patients with Hepatocellular Carcinoma
原文传递
导出
摘要 目的探讨人类白细胞抗原-G(human leukocyte antigen-G,HLA-G)在肝细胞肝癌组织中的表达及其在肝癌肝移植患者预后中的价值。方法回顾性分析2004年1月至2008年5月期间中山大学附属第三医院肝移植中心收治的83例肝癌肝移植患者的临床资料。应用免疫组化方法检测肝细胞肝癌组织及其癌旁组织中HLA-G的表达情况,应用Kaplan-Meier法计算累积生存率和无瘤生存率,采用log-rank检验和Cox回归模型分别进行无瘤生存率单因素和多因素分析。结果 83例肝癌肝移植患者中,35例(42.2%)肿瘤复发。全部病例1、3和5年累积生存率分别为97.2%、89.8%和43.1%,1、3和5年无瘤生存率分别为93.6%、68.9%和38.7%。肝癌组织中HLA-G表达阳性率(68.7%)明显高于癌旁组织(15.7%,P<0.01)。HLA-G的表达与肿瘤直径、病理分级和血管侵犯有关(P<0.05)。单因素分析显示,影响肝癌肝移植术后无瘤生存率的危险因素有HLA-G表达(P<0.01)、肿瘤直径(P<0.05)、肿瘤侵犯血管(P<0.01)及病理分化程度(P<0.01)。HLA-G表达阳性组移植后的无瘤生存率低于HLA-G表达阴性组(P<0.01)。Cox风险回归模型结果表明,HLA-G表达(P<0.05)、肿瘤侵犯血管(P<0.01)及病理分化程度(P<0.05)是影响肝癌肝移植患者术后无瘤生存率的独立危险因素。结论肝癌组织存在HLA-G表达。HLA-G表达、肿瘤侵犯血管及病理分化程度是影响肝癌肝移植患者术后无瘤生存率的独立危险因素。对HLA-G表达阳性患者采取干预治疗及严格筛选肝癌肝移植的适应证可有效降低术后肿瘤的复发率。 Objective To investigate the expression of human leukocyte antigen-G (HLA-G) in hepatocellular carcinoma (HCC) tissues, and to evaluate the prognosis of patients after liver transplantation. Methods The clinical data of 83 patients with HCC who underwent liver transplantation from January 2004 to May 2008 in the Liver Transplan- tation Center of the Third Affiliated Hospital of Sun Yat-sen University were analyzed retrospectively, The expression of HLA-G in HCC tissues was detected by using immunohistochemical analysis. The Kaplan-Meier method was used to evaluate the cumulative survival rate and tumor-free survival rate. Log-rank test and Cox regression model were used to analyze the single and muti-factor for tumor-free survival rate, respectively. Results Among the 83 patients, therewere tumor recurrence in 35 patients (42.2%). The 1-year, 3-year, and 5-year of cumulative survival rate was 97.2%, 89.8%, and 43.1%, respectively. The 1-year, 3-year, and 5-year of tumor-free survival rate was 93.6%, 68.9%, and 38.7%, respectively. The positive rate (68.7%) of HLA-G expression in HCC tissues was significantly higher than that in paracancerous tissues (15.7%), P 〈 0. 01. A significant association was found between expression of HLA-G and tumor size, vascular invasion, and pathology differentiation (P〈0. 05). Single factor analysis showed that the expres- sion ofHLA-G (P〈0. 01), tumor size (P〈0. 05), vascular invasion (P〈0.01), and pathology differentiation (P〈0. 01) effected on tumor-free survival rates of HCC patients after liver transplantation. The tumor-free survival rate in positive expression of HLA-G group was significantly lower than that in negative expression of HLA-G group (P〈 0. 01). Cox regression model analysis showed that the expression of HLA-G (P〈 0. 05), vascular invasion (P〈 0. 01), and pathol- ogy differentiation (P 〈 0. 05) were independent risk factors that affected the tumor-free survival rate of HCC patients after liver transplantation. Conclusions There is expression of HLA-G in HCC tissues. The independent risk factors that affecting the tumor-free survival rate of HCC patients after liver transplantation include the expression of HLA-G, vascular invasion, and pathological differentiation. Taking interferential measures for patients with positive expression of HLA-G and strict selection of indication of liver transplantation for HCC can reduce the recurrence rate of tumor.
出处 《中国普外基础与临床杂志》 CAS 2012年第7期712-717,共6页 Chinese Journal of Bases and Clinics In General Surgery
基金 国家重点基础研究发展规划(国家973规划)资助项目(项目编号:2009CB522404) 教育部博士点基金(项目编号:20100171-120087) 广东省自然科学基金(项目编号:10451130001004472) 增城市科技创新扶持基金(项目编号:ZC201004)~~
关键词 肝细胞肝癌 肝移植 预后 人类白细胞抗原-G 免疫组织化学 Hepatocellular carcinoma Liver transplantation Prognosis Human leukocyte antigen-G Immu-nohistochemistry
  • 相关文献

参考文献3

二级参考文献51

  • 1吴志全,樊嘉,邱双健,周俭,余耀,汤钊猷.肝癌肝移植病肝改良切除术[J].中华肝胆外科杂志,2005,11(11):782-783. 被引量:3
  • 2樊嘉,周俭,徐泱,邱双健,吴志全,余耀,黄晓武,汤钊猷,王玉琦.肝癌肝移植适应证的选择:上海复旦标准[J].中华医学杂志,2006,86(18):1227-1231. 被引量:121
  • 3贺轶锋,樊嘉,周俭,吴志全,邱双健,黄晓武,余耀,孙健,肖永胜,杨国欢,宋康,王征,汤钊猷,王玉琦.影响肝癌肝移植预后的高危因素分析及诊治经验[J].中华医学杂志,2006,86(18):1232-1235. 被引量:27
  • 4Kosola S,Lauronen J,Sairanen H,et al.High survival rates after liver transplantation for hepatoblastoma and hepatocel lular carcinoma[J].Pediatr Transplant,2010,14(5):646-650.
  • 5Coelho GR,Vasconcelos KF,Vasconcelos JB,et al.Orthotopic liver transplantation for hepatocellular carcinoma:one center's experience in the Northeast of Brazil[J].Transplant Proc,2009,41(5):1740-1742.
  • 6Mazzaferro V,Regalia E,Doci R.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J].N Engl J Med,1996,34(11):693-699.
  • 7Regalia E,Coppa J,Pulvirenti A,et al.Liver transplantation for small hepatocellular carcinoma in cirrhosis:analysis of our experience[J].Transplant Proc,2001,33(1-2):1442-1444.
  • 8Toso C,Trotter J,Wei A,et al.Total tumor volume prediets risk of recurrence following liver transplantation in patients with hepatocellular carcinoma[J].Liver Transpl,2008,14(8):1107-1115.
  • 9Yao FY,Ferrell L,Bass NM,et al.Liver transplantation for hepatocellular carcinoma:comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria[J].Liver Transpl,2002,8(9):765-774.
  • 10Iwatsuki S,Dvorchik I,Marsh JW,et al.Liver transplantalion for hepatocellular carcinoma:a proposal of a prognostic scoring system[J].J Am Coll Surg,2000,191(4):389394.

共引文献22

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部